Blueprint Medicines Corp (BPMC):企業の財務・戦略的SWOT分析

◆英語タイトル:Blueprint Medicines Corp (BPMC) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C15052
◆発行会社(調査会社):GlobalData
◆発行日:2019年3月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD300 ⇒換算¥39,900見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD600 ⇒換算¥79,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥119,700見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Blueprint Medicines Corp (Blueprint Medicines), formerly Hoyle Pharmaceuticals Inc, is a drug discovery company that develops drugs for the treatment of cancers and rare diseases. The company discovers and develops selective kinase inhibitors for genomically defined cancer subsets. Its pipeline products include BLU-554, used in advanced hepatocellular carcinoma; avapritinib, used in the treatment for unresectable, treatment-resistant gastrointestinal stromal tumors and advanced systemic mastocytosis; and BLU-667, for ret-mutations, fusions, and predicted resistant mutants. Its preclinical product candidate BLU-782 is intended for ALK2 mutations in fibrodysplasia ossificans progressiva. The company also discovers product candidates for kinase targets and immunokinase targets. The company operates through genomic and cancer research institutions located in the US. Blueprint Medicines is headquartered in Cambridge, Massachusetts, the US.

Blueprint Medicines Corp Key Recent Developments

Feb 26,2019: Blueprint Medicines reports fourth quarter and full year 2018 financial results
Jan 04,2019: Blueprint medicines announces “2020 blueprint” global business strategy and outlines key corporate goals
Oct 30,2018: Blueprint Medicines reports third quarter 2018 financial results
Oct 29,2018: Blueprint Medicines strengthens leadership with the appointments of Christina Rossi as chief commercial officer and Paul Beresford as general manager, international
Oct 01,2018: Blueprint Medicines Presents Foundational Preclinical Data Supporting the Development of BLU-782 a Highly Selective ALK2 Inhibitor for the Treatment of Patients with Fibrodysplasia Ossificans Progressiva

This comprehensive SWOT profile of Blueprint Medicines Corp provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Blueprint Medicines Corp including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Blueprint Medicines Corp – Key Information
Blueprint Medicines Corp – Overview
Blueprint Medicines Corp – Key Employees
Blueprint Medicines Corp – Key Employee Biographies
Blueprint Medicines Corp – Key Operational Heads
Blueprint Medicines Corp – Major Products and Services
Blueprint Medicines Corp – History
Blueprint Medicines Corp – Company Statement
Blueprint Medicines Corp – Locations And Subsidiaries
Blueprint Medicines Corp – Key Manufacturing facilities
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Blueprint Medicines Corp – Business Description
Blueprint Medicines Corp – Corporate Strategy
Blueprint Medicines Corp – SWOT Analysis
SWOT Analysis – Overview
Blueprint Medicines Corp – Strengths
Blueprint Medicines Corp – Weaknesses
Blueprint Medicines Corp – Opportunities
Blueprint Medicines Corp – Threats
Blueprint Medicines Corp – Key Competitors

Section 3 – Company Financial Performance Charts

Blueprint Medicines Corp – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Blueprint Medicines Corp, Key Information
Blueprint Medicines Corp, Key Ratios
Blueprint Medicines Corp, Share Data
Blueprint Medicines Corp, Major Products and Services
Blueprint Medicines Corp, History
Blueprint Medicines Corp, Key Employees
Blueprint Medicines Corp, Key Employee Biographies
Blueprint Medicines Corp, Key Operational Heads
Blueprint Medicines Corp, Other Locations
Blueprint Medicines Corp, Subsidiaries
Blueprint Medicines Corp, Key Manufacturing facilities
Blueprint Medicines Corp, Key Competitors
Blueprint Medicines Corp, SWOT Analysis
Blueprint Medicines Corp, Ratios based on current share price
Blueprint Medicines Corp, Annual Ratios
Blueprint Medicines Corp, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

Blueprint Medicines Corp, Performance Chart
Blueprint Medicines Corp, Ratio Charts

★海外企業調査レポート[Blueprint Medicines Corp (BPMC):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Ergon Inc:企業の戦略・SWOT・財務情報
    Ergon Inc - Strategy, SWOT and Corporate Finance Report Summary Ergon Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Abcam Plc (ABC):製薬・医療:M&Aディール及び事業提携情報
    Summary Abcam Plc (Abcam) is a supplier of life science research tools for analysis of living cells at molecular level to understand a wide range of disease conditions. The company develops and markets antibodies and other related products. Its product portfolio includes primary antibodies, secondar …
  • FLSmidth & Co AS (FLS):企業の財務・戦略的SWOT分析
    FLSmidth & Co AS (FLS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Impellam Group plc (IPEL):企業の財務・戦略的SWOT分析
    Impellam Group plc (IPEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Woori Bank:戦略・SWOT・企業財務分析
    Woori Bank - Strategy, SWOT and Corporate Finance Report Summary Woori Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Western Areas Limited:企業の戦略・SWOT・財務情報
    Western Areas Limited - Strategy, SWOT and Corporate Finance Report Summary Western Areas Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Leon’s Furniture Ltd (LNF):企業の財務・戦略的SWOT分析
    Leon's Furniture Ltd (LNF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • The Capital Group Companies, Inc.:企業の戦略・SWOT・財務情報
    The Capital Group Companies, Inc. - Strategy, SWOT and Corporate Finance Report Summary The Capital Group Companies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Matra Petroleum Plc:石油・ガス:M&Aディール及び事業提携情報
    Summary Matra Petroleum Plc (Matra Petroleum), formerly Ming Resources, is an independent oil and gas exploration and production company that acquires, explores, develops, and produces oil and gas properties in the US. The company owns 27 leases located in the Texas Panhandle region covering an area …
  • Jazz Pharmaceuticals Plc (JAZZ)-製薬・医療分野:企業M&A・提携分析
    Summary Jazz Pharmaceuticals plc (Jazz Pharmaceuticals) is a specialty biopharmaceutical company which identifies, develops and commercializes medicines with focus on narcolepsy, cancer, pain and psychiatry. Its major marketed products include Xyrem, sodium oxybate oral solution, for the treatment o …
  • Baylor Scott & White Health-製薬・医療分野:企業M&A・提携分析
    Summary Baylor Scott & White Health (Baylor Scott & White) is a non-profit organization that provides medical care services. The organization provides medical education, medical services and conducts medical research. It offers medical services in the area of emergency care, cancer care, behavioral …
  • Air Liquide SA (AI):企業の財務・戦略的SWOT分析
    Air Liquide SA (AI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Enel Generacion Chile SA (ENELGXCH):電力:M&Aディール及び事業提携情報
    Summary Enel Generacion Chile SA (Enel Generacion), formerly Empresa Nacional de Electricidad SA, is a power utility. It generates, distributes and sells electricity, exports natural gas, and provides various energy related products and services. The company produces electricity using hydro, gas, fu …
  • STADA Arzneimittel AG:企業の戦略・SWOT・財務情報
    STADA Arzneimittel AG - Strategy, SWOT and Corporate Finance Report Summary STADA Arzneimittel AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Momenta Pharmaceuticals Inc (MNTA):製薬・医療:M&Aディール及び事業提携情報
    Summary Momenta Pharmaceuticals Inc (Momenta) is a biotechnology company which specializes in the structural analysis, characterization, and design of complex pharmaceuticals. The company’s products include Glatopa; and Enoxaparin Sodium Injection. Its pipeline portfolio encompasses candidates to su …
  • Globe Telecom, Inc.:企業の戦略・SWOT・財務情報
    Globe Telecom, Inc. - Strategy, SWOT and Corporate Finance Report Summary Globe Telecom, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • First Abu Dhabi Bank PJSC (FAB):企業の財務・戦略的SWOT分析
    First Abu Dhabi Bank PJSC (FAB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • InterDigital, Inc. (IDCC):企業の財務・戦略的SWOT分析
    InterDigital, Inc. (IDCC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Marshall of Cambridge (Holdings) Ltd:戦略・SWOT・企業財務分析
    Marshall of Cambridge (Holdings) Ltd - Strategy, SWOT and Corporate Finance Report Summary Marshall of Cambridge (Holdings) Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Axela Inc-医療機器分野:企業M&A・提携分析
    Summary Axela Inc (Axela), formerly Axela Biosensors Inc is a provider of optic technology solutions. The company offers Ziplex system, Flow-thru TipChips, panelPlus TipChips, diffractive optics technology, diffractive optics sensors, panelPlus sensors and software products. It offers technical and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆